Non‐BCMA targeted CAR‐T cell therapies for multiple myeloma
Abstract Despite the emergence of new strategies in recent years, multiple myeloma (MM) is still an incurable disease with poor outcome. As a new treatment, chimeric antigen receptor (CAR‐) T cell therapy brought exciting news to patients with relapsed or refractory MM. B‐cell maturation antigen (BC...
| Main Authors: | , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2021-12-01
|
| Series: | ImmunoMedicine |
| Subjects: | |
| Online Access: | https://doi.org/10.1002/imed.1030 |